Theme

Tegoprazan matched lansoprazole for preventing NSAID-related peptic ulcers over 24 weeks, with comparable safety.

Source
Source: No source documents or extracted text were provided.

Hero fact: Tegoprazan was non-inferior to lansoprazole for preventing NSAID-induced gastroduodenal ulcers at week 24.

392

Patients randomized 1:1

24 weeks

Gastroprotection follow-up

p=0.0004

Non-inferiority met

Why it matters

Long-term NSAID therapy increases peptic ulcer risk, especially in chronic users who need continuous pain or inflammation control.

Effective gastroprotection can help patients remain on necessary NSAID therapy while reducing ulcer-related complications.

Study snapshot

Phase III, randomized, double-blind, active-controlled, multicenter trial comparing tegoprazan with lansoprazole for up to 24 weeks.

Tegoprazan
25 mg once daily
Lansoprazole
15 mg once daily

Efficacy and symptoms

Endpoint Finding Clinical readout
Gastroduodenal ulcer prevention at week 24 Non-inferior to lansoprazole Primary endpoint met
Heartburn-free rate at week 12 Higher with tegoprazan Symptom signal favored tegoprazan
Other GI symptom-free rates No significant difference Broad symptom control comparable

Safety and clinical meaning

Adverse drug reactions
Similar between groups
Serious adverse events
Similar between groups

In the per-protocol population of 269 patients, tegoprazan maintained ulcer-prevention efficacy without a safety penalty versus lansoprazole.

Takeaway

For patients needing continuous long-term NSAID therapy, tegoprazan 25 mg appears to be a clinically effective and well-tolerated gastroprotective alternative to lansoprazole 15 mg.